South Lakeland MP Tim Farron has called for pharmaceutical company GlaxoSmithKline (GSK) to leave a dowry behind to make future investment in the site more attractive for a potential buyer and to support local jobs.
This week GSK shocked the area by pulling out of a planned £350million investment in the Ulverston site which would have supported hundreds of local jobs.
Tim Farron says the local community is still reeling from the news:
South Lakeland District Council (SLDC) say they are 'shocked and disappointed' at pharmaceutical giant, GlaxoSmithKine's (GSK) decision to pull out its investment from its Ulverston site in Cumbria.
SLDC’s portfolio holder for the economy, Councillor Graham Vincent, said the news was a blow. He said the council's concern now is to understand the implications for the future of the current site and the existing GSK employees in Ulverston.
The SLDC's chief executive spoke to GSK management who have said there will be no immediate impact on the existing workforce and the site does remain profitable. The council have said they will assist the company in finding a buyer, to continue the operation of the facility, should they decide to sell up.
For more updates on this story visit the ITV News Granada website
GSK today confirmed that it will invest more than £500m in the UK across its manufacturing sites to increase production of key active ingredients for its pharmaceutical products and vaccines.
The company announced selection of Ulverston in Cumbria as the location for the first new GSK manufacturing facility to be built in the UK for almost 40 years.
- In total more than £500m of investment confirmed, creating up to 1,000 new jobs.
- Includes £100m investment for GSK manufacturing in Scotland.
Investment will also be made at the company’s two manufacturing sites in Scotland at Montrose and Irvine. In total, it is anticipated these investments will create up to 1,000 new jobs over the lifetime of the projects.